Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DM6OLGC)

Drug Name

MK-3207 Drug Info

Synonyms

957116-20-0; MK-3207 Hydrochloride; MK-3207 (Hydrochloride); MK-3207 HCl; MK-3207 HCl salt; 2-((R)-8-(3,5-Difluorophenyl)-10-oxo-6,9-diazaspiro[4.5]decan-9-yl)-N-((R)-2'-oxo-1,1',2',3-tetrahydrospiro[indene-2,3'-Pyrrolo[2,3-b]pyridin]-5-yl)acetamide hydrochloride; MK3207; (8R)-8-(3,5-Difluorophenyl)-10-oxo-n-[(2r)-1,1',2',3-tetrahydro-2'-oxospiro[2h-indene-2,3'-[3h]pyrrolo[2,3-b]pyridin]-5-yl]-6,9-diazaspiro[4.5]decane-9-acetamide hydrochloride; MK 3207 hydrochloride; MK-3207(Hydrochloride); MK3207 HCl

Indication

Disease Entry	ICD 11	Status	REF
Migraine	8A80	Phase 2	[1]

Cross-matching ID

PubChem CID: 25019940
CAS Number: CAS 957118-49-9
TTD Drug ID: DM6OLGC

Molecule-Related Drug Atlas

Molecule Type:

DTT

Drug Status:

Approved Drug(s)

Clinical Trial Drug(s)

Download the Complete Related Drug List

Drug(s) Targeting Calcitonin gene-related peptide receptor (CGRPR)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Ubrogepant	DM749I3	Migraine	8A80	Approved	[3]
Fremanezumab	DMDZY54	Hyperprolactinaemia	5A60.1	Approved	[4]
Galcanezumab	DMIZ1E8	Hyperprolactinaemia	5A60.1	Approved	[4]
Erenumab	DMWMCN0	Hyperprolactinaemia	5A60.1	Approved	[4]
Rimegepant	DMHOAUG	Migraine	8A80	Approved	[5]
AMG 334	DMI3WFG	Migraine	8A80	Phase 2	[6]
Telcagepant	DMFT5D6	Cluster headache	8A81.0	Phase 2	[7]
Olcegepant	DMVW5KR	Migraine	8A80	Phase 2	[8]
BI-44370	DMZR9OU	Migraine	8A80	Phase 2	[9]
LBR-101	DM4YA0D	Migraine	8A80	Phase 1	[10]
------------------------------------------------------------------------------------


⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Calcitonin gene-related peptide receptor (CGRPR)	TTY6O0Q	CALRL_HUMAN	Antagonist	[2]

------------------------------------------------------------------------------------

References

1	ClinicalTrials.gov (NCT00712725) MK3207 for Treatment of Acute Migraines (3207-005). U.S. National Institutes of Health.
2	Pharmacological properties of MK-3207, a potent and orally active calcitonin gene-related peptide receptor antagonist. J Pharmacol Exp Ther. 2010 Apr;333(1):152-60.
3	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2019
4	2018 FDA drug approvals.Nat Rev Drug Discov. 2019 Feb;18(2):85-89.
5	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2020
6	EHMTI-0315. AMG 334, the first potent and selective human monoclonal antibody antagonist against the CGRP receptor. J Headache Pain. 2014; 15(Suppl 1): G43.
7	CGRP antagonists: novel concept for treatment of migraine. Med Monatsschr Pharm. 2009 May;32(5):182-5.
8	Olcegepant, a non-peptide CGRP1 antagonist for migraine treatment. IDrugs. 2007 Aug;10(8):566-74.
9	BI 44370 TA, an oral CGRP antagonist for the treatment of acute migraine attacks: results from a phase II study. Cephalalgia. 2011 Apr;31(5):573-84.
10	Safety and tolerability of LBR-101, a humanized monoclonal antibody that blocks the binding of CGRP to its receptor: Results of the Phase 1 program. Cephalalgia. 2013 Dec 23;34(7):483-492.